J.M. Hartwell’s Vertex Pharmaceuticals VRTX Stock Holding History

J.M. Hartwell’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,500	Closed	-$255K	–	88
2018 Q2	$255K	Buy	+1,500	New	+$233K	0.05%	77
2017 Q4	–	Sell	-3,000	Closed	-$456K	–	87
2017 Q3	$456K	Sell	3,000 -1,000	-25%	-$151K	0.09%	65
2017 Q2	$515K	Buy	+4,000	New	+$482K	0.11%	61

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

J.M. Hartwell's VRTX Position: Q3 2018 in Review

J.M. Hartwell sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 1,500 shares — an estimated $255K sold.

J.M. Hartwell first reported a position in VRTX in Q2 2017 and held it in 3 quarters. The position peaked at $515K in Q2 2017. 696 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

J.M. Hartwell reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
J.M. Hartwell sold 1,500 Vertex Pharmaceuticals shares in Q3 2018, an estimated $255K.
J.M. Hartwell first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 3 quarters.
J.M. Hartwell's Vertex Pharmaceuticals position peaked at $515K in Q2 2017.
696 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on J.M. Hartwell's 13F filing for Q3 2018, filed 29 Oct 2018.